Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep - Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed (ASX:IMM)

SYDNEY, AUSTRALIA – October 03, 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing no...read more

Immutep receives A$3.6 million French R&D Tax Incentive (ASX:IMM)

SYDNEY, AUSTRALIA - 24 September 2024 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 r...read more

Immutep - Data to be presented from Ph II trial in Soft Tissue Sarcoma (ASX:IMM)

Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society 2024 Annual Meeting EFTISARC-N...read more

Immutep - New Positive Efficacy Data for Efti in Head and Neck Cancer (ASX:IMM)

Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024 In patients with any PD-L1 expression (CPS ≥1), efti in combination with KEYTRUDA ou...read more

Immutep - S&P DJI Announces September 2024 Quarterly Rebalance (ASX:IMM)

S&P Dow Jones Indices announced today the changes in the S&P/ASX Indices, effective prior to the opening of trading on Monday, September 23, 2024, as a result of the September quarterly revi...read more

Immutep - Appendix 4E & 2024 Full Year Statutory Accounts (ASX:IMM)

To view the appendix, download the attached PDF.

IVE Group - Updated Securities Dealing Policy (ASX:IGL)

In accordance with ASX Listing Rule 12.10, IVE Group Limited (ASX:IGL) attaches a copy of its updated Securities Dealing Policy, with the only change being the expansion of the trading windows. The ...read more

IVE Group - 2024 Corporate Governance Statement and Appendix 4G (ASX:IGL)

To view the appendix, download the attached PDF.

IVE Group - FY24 Results Presentation (ASX:IGL)

To view the presentation, download the attached PDF.

IVE Group - Financial Results for the Year Ending 30 June 2024 (ASX:IGL)

Financial results for the Year Ending 30 June 2024 IVE Group Limited is pleased to announce its financial results for the year ended 30 June 2024 (FY24). Excluding non-operating items, the Gro...read more

IVE Group - Dividend/Distribution (ASX:IGL)

Distribution Amount: AUD 0.08500000 For more information, download the attached PDF.

IVE Group - Appendix 4E & Financial Statements - Year ended 30 June 2024 (ASX:IGL)

Company Information Current Reporting Period: For the year ended 30 June 2024 Prior Corresponding Period: For the year ended 30 June 2023 This information should be read in conjunction with...read more

INOVIQ - Appendix 4E and Preliminary Financial Report (ASX:IIQ)

To view the appendix, download the attached PDF.

Immutep Corporate Presentation (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep - TACTI-003 data selected for oral presentation at ESMO 2024 (ASX:IMM)

Oral presentation will detail results from the randomized TACTI-003 Phase IIb trial in first line head & neck squamous cell carcinoma patients with any PD-L1 expression (CPS >...read more

Viewing: 1 - 15 of 200 Previous | Next